The Effects Of Fx-1006A On Transthyretin Stabilization And Clinical Outcome Measures In Patients With V122I Or Wild-Type TTR Amyloid Cardiomyopathy.
Phase of Trial: Phase II
Latest Information Update: 01 May 2015
At a glance
- Drugs Tafamidis meglumine (Primary)
- Indications Cardiomyopathies; Heart failure
- Focus Pharmacodynamics
- 31 Aug 2018 Biomarkers information updated
- 15 Jun 2011 Company (Pfizer) added in the association field as reported by ClinicalTrials.gov.
- 09 Oct 2008 Planned number of patients changed from 20 to 40, based on information from ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History